CN104876921A - 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 - Google Patents
作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 Download PDFInfo
- Publication number
- CN104876921A CN104876921A CN201510174069.0A CN201510174069A CN104876921A CN 104876921 A CN104876921 A CN 104876921A CN 201510174069 A CN201510174069 A CN 201510174069A CN 104876921 A CN104876921 A CN 104876921A
- Authority
- CN
- China
- Prior art keywords
- compound
- mmol
- methyl
- alkyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(C)(C1)**C*(*)C1NC Chemical compound C*(C)(C1)**C*(*)C1NC 0.000 description 14
- MPIGVTXPFIYPEX-ZZWBGTBQSA-N CC(C)NCC(Cc(cc1)ccc1-c1c([C@H](C)CC2)c2ncn1)c(cc1)ccc1Cl Chemical compound CC(C)NCC(Cc(cc1)ccc1-c1c([C@H](C)CC2)c2ncn1)c(cc1)ccc1Cl MPIGVTXPFIYPEX-ZZWBGTBQSA-N 0.000 description 1
- TUXHVZBAOQBYKQ-KPHZKDQSSA-N CC(C)NCC(c(cc1)ccc1Cl)Nc(cc1)ccc1-c1c([C@H](C)C[C@H]2O)c2ncn1 Chemical compound CC(C)NCC(c(cc1)ccc1Cl)Nc(cc1)ccc1-c1c([C@H](C)C[C@H]2O)c2ncn1 TUXHVZBAOQBYKQ-KPHZKDQSSA-N 0.000 description 1
- SFDIQVMDLDFYKS-SSKADXOYSA-N CC(C)NCC(c1n[s]c2cc(-c3c([C@H](C)C[C@H]4O)c4ncn3)ccc12)c(cc1)ccc1Cl Chemical compound CC(C)NCC(c1n[s]c2cc(-c3c([C@H](C)C[C@H]4O)c4ncn3)ccc12)c(cc1)ccc1Cl SFDIQVMDLDFYKS-SSKADXOYSA-N 0.000 description 1
- DZYJIWRJVATRJC-SXSPYAJSSA-N C[C@H](C1)c2c(C(CC3)=CCN3C([C@H](C[N]3(CC3)C(C)(C)C)c(cc3)ccc3Br)=O)ncnc2[C@@H]1O Chemical compound C[C@H](C1)c2c(C(CC3)=CCN3C([C@H](C[N]3(CC3)C(C)(C)C)c(cc3)ccc3Br)=O)ncnc2[C@@H]1O DZYJIWRJVATRJC-SXSPYAJSSA-N 0.000 description 1
- WRGHYZWPWNOJEF-UHFFFAOYSA-N Cc1nnc2[n]1CCNC2 Chemical compound Cc1nnc2[n]1CCNC2 WRGHYZWPWNOJEF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2012908P | 2008-01-09 | 2008-01-09 | |
| US61/020,129 | 2008-01-09 | ||
| CN2009801083210A CN101970415A (zh) | 2008-01-09 | 2009-01-09 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801083210A Division CN101970415A (zh) | 2008-01-09 | 2009-01-09 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104876921A true CN104876921A (zh) | 2015-09-02 |
Family
ID=40578062
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510174069.0A Pending CN104876921A (zh) | 2008-01-09 | 2009-01-09 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
| CN2009801083210A Pending CN101970415A (zh) | 2008-01-09 | 2009-01-09 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801083210A Pending CN101970415A (zh) | 2008-01-09 | 2009-01-09 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8329709B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2250155B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5635910B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104876921A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2711782C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2426092T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009089462A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021185238A1 (zh) | 2020-03-17 | 2021-09-23 | 江苏恒瑞医药股份有限公司 | 稠合二环类衍生物、其制备方法及其在医药上的应用 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2692502C (en) * | 2007-07-05 | 2016-03-01 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| WO2009089352A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| CN104876921A (zh) | 2008-01-09 | 2015-09-02 | 阵列生物制药公司 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
| EP2242757B1 (en) | 2008-01-09 | 2012-08-01 | Array Biopharma, Inc. | Pyrazolopyridines as kinase inhibitors |
| WO2010016554A1 (ja) * | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | 環状アミン化合物 |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| CA2793313C (en) | 2010-04-02 | 2018-01-23 | Euroscreen Sa | Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| CA2849751C (en) * | 2011-10-03 | 2019-06-11 | Euroscreen Sa | Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof |
| US9422267B2 (en) | 2012-12-26 | 2016-08-23 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| WO2016003827A2 (en) * | 2014-07-02 | 2016-01-07 | Medivation Technologies, Inc. | Fused cycloalkyl-pyrimidine compounds and uses thereof |
| JP6469214B2 (ja) | 2014-09-25 | 2019-02-13 | オゲダ エス.エー. | N−アシル−(3−置換)−(8−置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジンの新規キラル合成 |
| US12617784B2 (en) | 2019-01-29 | 2026-05-05 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT inhibitor |
| JP7397183B2 (ja) * | 2019-10-22 | 2023-12-12 | 昊運股▲フン▼有限公司 | ピリミジンアミド化合物及びその使用 |
| GB201918815D0 (en) * | 2019-12-19 | 2020-02-05 | Imperial College Innovations Ltd | Treatment of cancer |
| CN115485276B (zh) * | 2020-05-15 | 2024-05-31 | 南京正大天晴制药有限公司 | 氘代akt激酶抑制剂 |
| CN111533745A (zh) * | 2020-05-20 | 2020-08-14 | 成都药明康德新药开发有限公司 | 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法 |
| EP4186902A4 (en) | 2020-07-22 | 2024-06-05 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE SALT, PREPARATION METHOD AND USE THEREOF |
| US12673061B2 (en) | 2020-07-22 | 2026-07-07 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Unit dosage composition of AKT inhibitor |
| WO2023109540A1 (zh) * | 2021-12-17 | 2023-06-22 | 中国医药研究开发中心有限公司 | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 |
| WO2023244430A1 (en) * | 2022-06-14 | 2023-12-21 | Alphala Co., Ltd. | Pyrimidine amide compounds and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| AU2001290912A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1571146A4 (en) * | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
| AU2004293026B2 (en) * | 2003-11-21 | 2012-01-19 | Array Biopharma Inc. | AKT protein kinase inhibitors |
| WO2005113762A1 (en) | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| AU2005322085B2 (en) * | 2004-12-28 | 2012-07-19 | Exelixis, Inc. | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| WO2007076423A2 (en) * | 2005-12-22 | 2007-07-05 | Smithkline Beecham Corporation | INHIBITORS OF Akt ACTIVITY |
| JP2009534454A (ja) * | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US7851468B2 (en) * | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
| RU2481336C2 (ru) | 2006-07-06 | 2013-05-10 | Эррэй Биофарма Инк. | Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт |
| DE602007011628D1 (de) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| WO2008006039A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| US20130065908A1 (en) | 2009-12-07 | 2013-03-14 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US20090118135A1 (en) | 2007-06-08 | 2009-05-07 | The Burnham Institute | Methods and compounds for regulating apoptosis |
| MX2009014013A (es) | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| CA2692502C (en) | 2007-07-05 | 2016-03-01 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CN104876921A (zh) | 2008-01-09 | 2015-09-02 | 阵列生物制药公司 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
| US8835434B2 (en) | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US20160152574A9 (en) | 2008-01-09 | 2016-06-02 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| AR072657A1 (es) | 2008-02-29 | 2010-09-15 | Genentech Inc | Compuestos inhibidores de raf y metodos para su uso |
| JPWO2009154207A1 (ja) * | 2008-06-17 | 2011-12-01 | 出光興産株式会社 | アントラセン誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| US20150051217A1 (en) | 2010-07-07 | 2015-02-19 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
-
2009
- 2009-01-09 CN CN201510174069.0A patent/CN104876921A/zh active Pending
- 2009-01-09 CA CA2711782A patent/CA2711782C/en not_active Expired - Fee Related
- 2009-01-09 ES ES09701043T patent/ES2426092T3/es active Active
- 2009-01-09 WO PCT/US2009/030617 patent/WO2009089462A1/en not_active Ceased
- 2009-01-09 US US12/812,377 patent/US8329709B2/en active Active
- 2009-01-09 EP EP09701043.3A patent/EP2250155B1/en active Active
- 2009-01-09 CN CN2009801083210A patent/CN101970415A/zh active Pending
- 2009-01-09 JP JP2010542377A patent/JP5635910B2/ja active Active
-
2012
- 2012-11-15 US US13/678,395 patent/US8895566B2/en active Active
-
2014
- 2014-08-28 JP JP2014173596A patent/JP2015007097A/ja active Pending
- 2014-10-24 US US14/523,481 patent/US9328091B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021185238A1 (zh) | 2020-03-17 | 2021-09-23 | 江苏恒瑞医药股份有限公司 | 稠合二环类衍生物、其制备方法及其在医药上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8895566B2 (en) | 2014-11-25 |
| CN101970415A (zh) | 2011-02-09 |
| US20110251181A1 (en) | 2011-10-13 |
| US8329709B2 (en) | 2012-12-11 |
| CA2711782C (en) | 2017-01-03 |
| EP2250155A1 (en) | 2010-11-17 |
| JP2015007097A (ja) | 2015-01-15 |
| US20130085135A1 (en) | 2013-04-04 |
| WO2009089462A1 (en) | 2009-07-16 |
| US9328091B2 (en) | 2016-05-03 |
| US20150266852A1 (en) | 2015-09-24 |
| JP5635910B2 (ja) | 2014-12-03 |
| HK1150605A1 (en) | 2012-01-06 |
| EP2250155B1 (en) | 2013-07-03 |
| JP2011509309A (ja) | 2011-03-24 |
| ES2426092T3 (es) | 2013-10-21 |
| CA2711782A1 (en) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101970415A (zh) | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 | |
| CN101918373B (zh) | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 | |
| CN101801955B (zh) | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 | |
| CN101631778B (zh) | 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶 | |
| CN110603258A (zh) | 抑制g12c突变型ras蛋白的杂芳基化合物 | |
| AU2021269397B2 (en) | Compounds and compositions for the treatment of cancer | |
| HK1150605B (en) | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors | |
| HK1147255B (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | |
| HK1136832B (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150902 |